Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 31.
doi: 10.1111/ijd.70126. Online ahead of print.

Super-Response to Guselkumab Treatment in Patients With Moderate-to-Severe Psoriasis: Real-World Data With Up to Five Years of Follow-Up in The Czech Republic

Martina Kojanova  1 , Daniela Pejrilova  2 , Jorga Fialova  1 , Petra Cetkovska  3 , Spyridon Gkalpakiotis  4 , Alena Machovcova  5 , Petr Arenberger  4 , Jiri Stork  1 , Tomas Dolezal  2 , Martin Tichy  6   7 ; BIOREP study group
Collaborators, Affiliations

Super-Response to Guselkumab Treatment in Patients With Moderate-to-Severe Psoriasis: Real-World Data With Up to Five Years of Follow-Up in The Czech Republic

Martina Kojanova et al. Int J Dermatol. .

Abstract

Background: Guselkumab, a selective interleukin (IL)-23 inhibitor, is approved for the treatment of moderate-to-severe plaque psoriasis. While randomized clinical trials have introduced the concept of "super-responders" (SRe)-patients achieving complete skin clearance (Psoriasis Area and Severity Index [PASI] 100) at defined early timepoints-real-world evidence on their characteristics and long-term outcomes remains limited. This study aimed to identify baseline predictors of super-response (PASI 100 at Weeks 16 and 24) and to evaluate long-term effectiveness, safety, and drug survival over a 5-year period in a routine clinical setting.

Methods: This retrospective multicenter study analyzed 435 patients from the Czech BIOREP registry treated with guselkumab. Predictors of super-response were identified using multivariable logistic regression. PASI outcomes and drug survival were assessed with descriptive statistics and Kaplan-Meier analysis.

Results: Among the cohort, 130 patients (29.9%) were classified as super-responders. Lower body mass index (BMI) and absence of prior biologic therapy were independent predictors of SRe status (odds ratio [OR] = 0.94 and 0.73, respectively). While PASI 75/90/100 rates were significantly higher in SRe throughout follow-up, drug survival was comparable between SRe and non-SRe. At 60 months, PASI 100 was maintained in 79.2% of SRe versus 35.4% of non-SRe. Obesity and female sex were associated with lower long-term treatment persistence.

Conclusions: Super-response to guselkumab is linked to distinct baseline features. Despite differences in PASI outcomes, treatment persistence was similar across groups. These findings underscore the value of early identification of super-responders and support personalized treatment strategies in clinical practice.

Keywords: BIOREP; guselkumab; psoriasis; real‐world; registries; super‐response.

PubMed Disclaimer

References

    1. W.‐H. Boehncke and M. P. Schön, “Psoriasis,” Lancet 386, no. 9997 (2015): 983–994.
    1. S. K. Kurd, A. B. Troxel, P. Crits‐Christoph, and J. M. Gelfand, “The Risk of Depression, Anxiety, and Suicidality in Patients With Psoriasis: A Population‐Based Cohort Study,” Archives of Dermatology 146, no. 8 (2010): 891–895.
    1. L. S. Winterfield, A. Menter, K. Gordon, and A. Gottlieb, “Psoriasis Treatment: Current and Emerging Directed Therapies,” Annals of the Rheumatic Diseases 64 Suppl 2 (2005): ii87–ii90.
    1. J. M. Benson, D. Peritt, B. J. Scallon, et al., “Discovery and Mechanism of Ustekinumab: A Human Monoclonal Antibody Targeting Interleukin‐12 and Interleukin‐23 for Treatment of Immune‐Mediated Disorders,” MAbs 3, no. 6 (2011): 535–545.
    1. A. A. Gaspari and S. Tyring, “New and Emerging Biologic Therapies for Moderate‐to‐Severe Plaque Psoriasis: Mechanistic Rationales and Recent Clinical Data for IL‐17 and IL‐23 Inhibitors,” Dermatologic Therapy 28, no. 3 (2015): 179–193.

LinkOut - more resources